Educational only. Not medical advice.
On October 12, 2026, Bristol Myers Squibb announced positive topline results from a planned interim analysis of ACTION-1, a Phase 3 trial of an investigational therapy called RYZ101. The post spread quickly on X with the headline that a "radioactive peptide" had succeeded in Phase 3. The result is real and notable. Here is what it actually says, and what it doesn't.
What was announced
- The therapy: RYZ101 (from RayzeBio, a BMS company) pairs DOTATATE, a somatostatin-analogue peptide, with actinium-225, an alpha-emitting radioisotope.
- The trial: ACTION-1 (NCT05477576) is a randomized Phase 3 study comparing RYZ101 with investigator's choice of standard care. Comparators were high-dose or high-frequency long-acting somatostatin analogues, everolimus or sunitinib.
- The patients: adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) whose disease had progressed after lutetium-177-based therapy.
- The result: the interim analysis met its primary endpoint, a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review.
- Safety: described as consistent with the known safety profile of RYZ101.
How a peptide fits in
Here the peptide is the guidance system. Neuroendocrine tumor cells carry many somatostatin receptors on their surface. DOTATATE binds to those receptors, so it carries the attached radioisotope to the tumor cells. Actinium-225 emits alpha particles, which have high energy and a very short range, and can cause double-strand DNA damage in the cells they reach. This approach is called targeted radiopharmaceutical therapy.
What the announcement does not say
- It does not report a hazard ratio, median progression-free survival or sample size. Those are expected at a future medical meeting.
- It does not show an overall survival benefit yet. Patients will continue to be followed for that.
- It is not an approval. BMS says it plans to engage the FDA on next steps. The FDA granted RYZ101 Orphan Drug Designation for GEP-NETs in August 2026.
- It is a topline press-release result, not a peer-reviewed publication.
Why it matters for peptide medicine
The company describes these as the first Phase 3 results for an alpha-isotope targeted radiopharmaceutical in any indication. For peptide science more broadly, it is a reminder that peptides can be developed into serious medicines when they go through the full process: rigorous trials, independent endpoint review and regulatory scrutiny.
What this is not
RYZ101 is a specialized investigational drug given in a clinical setting for a specific cancer. It is not related to wellness or recovery peptides, and this result says nothing about the safety or effectiveness of any other peptide. A positive trial for one compound does not carry over to others. Each compound needs its own evidence.
The takeaway
The standard to look for is the same everywhere: well-designed human trials, transparent results and clinician oversight. When you see a viral headline about peptides, check the source, look for the numbers and see whether the claim matches the study. If you are interested in prescription peptides, a licensed clinician and a licensed US pharmacy are where that conversation belongs.
Sources: Bristol Myers Squibb press release · CancerNetwork
0 comments